WASHINGTON — The Food and Drug Administration on Thursday announced the first nine recipients of the Commissioner’s National Priority Review vouchers, a program offering an expedited drug review to companies with products that align with the agency’s national health priorities.
President Trump highlighted one of the recipients, EMD Serono, at a White House news conference on expanding access to in vitro fertilization on Thursday. EMD Serono agreed to lower the prices of its existing fertility drugs. In exchange, the company received a voucher for Pergoveris, which stimulates egg development and has already been approved in 74 countries.
The other drugs on the list are:
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
Source link
